Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 35
What experts said about CJC-1295 in Q2 2026
On-record expert commentary on CJC-1295 from Q2 2026: the evidence gap, cancer-risk concerns, regulatory shifts, and the upcoming PCAC review.
Ipamorelin: what experts said, Q2 2026
On-record expert commentary on ipamorelin from Q2 2026, with credentials, conflicts of interest, and the FDA regulatory picture.
Oral semaglutide for weight loss, reviewed
A Postgraduate Medicine review examines the trial evidence, dosing requirements, and practical considerations for using oral semaglutide in weight management.
Peptides for nerve recovery after surgery
BPC-157, TB-500, and ARA 290 are discussed in recovery communities after nerve surgery. Here is what preclinical and early clinical evidence actually shows.
What experts said about PT-141 in Q2 2026
On-record expert commentary on PT-141 from Q2 2026: arguments for male trials, a Harvard meta-analysis, and Palatin's obesity pivot.
Why your Semax or Selank spray smells off
A fishy or sulfurous smell from a pre-mixed peptide nasal spray usually signals degradation. The methionine chemistry explains why.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
BPC-157 tested as AChE inhibitor in vitro
A 2026 lab study finds BPC-157 and two hybrid peptides inhibit the enzyme targeted by Alzheimer's drugs, but at low potency and only in vitro.
Which drugs flag for gastric motility risks
A 2026 study screened 58 million adverse-event reports. Semaglutide had the strongest signal for impaired gastric emptying.
Herbs for GLP-1 side effects? A new study
Researchers screened 142,705 FDA adverse event reports to flag five herbal candidates linked to GLP-1 side-effect pathways.
Oral Wegovy tracker: FDA, EMA, MHRA
The FDA, EMA, and MHRA have now all approved oral Wegovy for weight management. Here is the regulatory timeline and how the three decisions compare.
Radiolabeling peptides in fewer steps
A 2026 study reports a hydroformylation method that installs carbon-14 or tritium labels on peptides, including semaglutide analogs.